Damora Therapeutics (DMRA) Net Cash Flow (2019 - 2026)

Damora Therapeutics has reported Net Cash Flow for 8 years, with the latest figure at $275.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 11571.71% year-over-year to $275.3 million; the trailing twelve-month figure through Mar 2026 stood at $271.0 million (up 3077.97% YoY), and the FY2025 full-year result was $242.7 million, up 3592.72% from the prior year.
• Net Cash Flow for Q1 2026 stood at $275.3 million, up from $574000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $275.3 million in Q1 2026, with the low at -$17.0 million in Q1 2022.
• Historically, Net Cash Flow has averaged $12.9 million across 5 years, with a median of -$2.1 million in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow sank 184450.0% — and 2026, when it jumped 11571.71%.
• Damora Therapeutics' Net Cash Flow stood at $2.9 million in 2022, then slumped by 163.9% to -$1.9 million in 2023, then slumped by 160.91% to -$4.9 million in 2024, then surged by 111.68% to $574000.0 in 2025, then soared by 47865.33% to $275.3 million in 2026.
• The last three Net Cash Flow figures came in at $275.3 million (Q1 2026), $574000.0 (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.